Which statement best describes typical antipsychotics?

Which statement best describes typical antipsychotics?

• A. They have a wider receptor affinity than atypical antipsychotics.
• B. They primarily help manage negative symptoms of psychosis.
• C. They are older first-generation drugs with prominent side effects.
• D. They have fewer neurological side effects compared to atypical drugs.

Answer: (C)

The statement identifying typical antipsychotics as older first-generation drugs with prominent side effects is accurate and captures a key aspect of these medications. Typical antipsychotics, such as haloperidol and chlorpromazine, were among the first medications developed for the treatment of psychotic disorders. They primarily target the dopamine receptors in the brain, specifically D2 receptors, leading to a significant reduction in positive symptoms like hallucinations and delusions. However, their effectiveness in managing positive symptoms comes with the risk of notable side effects, particularly extrapyramidal symptoms (EPS) such as tremors, rigidity, and tardive dyskinesia. These side effects arise from the drugs' dopamine antagonism in pathways associated with motor control. This characteristic distinguishes them from atypical antipsychotics, which generally have a broader spectrum of receptor activity and tend to cause fewer EPS, though they may still have side effects of their own. In contrast, the other statements do not accurately characterize typical antipsychotics. For example, the assertion about their wider receptor affinity is incorrect; atypical antipsychotics are known for their broader receptor interactions. Similarly, stating that typical antipsychotics primarily manage negative symptoms misrepresents their primary function, which is

The statement identifying typical antipsychotics as older first-generation drugs with prominent side effects is accurate and captures a key aspect of these medications. Typical antipsychotics, such as haloperidol and chlorpromazine, were among the first medications developed for the treatment of psychotic disorders. They primarily target the dopamine receptors in the brain, specifically D2 receptors, leading to a significant reduction in positive symptoms like hallucinations and delusions.

However, their effectiveness in managing positive symptoms comes with the risk of notable side effects, particularly extrapyramidal symptoms (EPS) such as tremors, rigidity, and tardive dyskinesia. These side effects arise from the drugs' dopamine antagonism in pathways associated with motor control. This characteristic distinguishes them from atypical antipsychotics, which generally have a broader spectrum of receptor activity and tend to cause fewer EPS, though they may still have side effects of their own.

In contrast, the other statements do not accurately characterize typical antipsychotics. For example, the assertion about their wider receptor affinity is incorrect; atypical antipsychotics are known for their broader receptor interactions. Similarly, stating that typical antipsychotics primarily manage negative symptoms misrepresents their primary function, which is